文献速递白血病淋巴瘤血栓与止血

接受依鲁替尼治疗的慢性淋巴细胞白血病和套细胞淋巴瘤患者的血小板功能与出血

Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib.
PubMed 文献 · J Thromb Haemost · 2020-01-01

研究纳入50例慢性淋巴细胞白血病(CLL)和16例套细胞淋巴瘤(MCL)患者,用流式细胞术和光透射聚集法评估依鲁替尼治疗期间血小板功能。CLL中28例(56%)出血,与治疗前ADP聚集和血小板计数降低相关;MCL中10例(62%)出血,与治疗前致密颗粒释放降低相关。作者认为CLL出血涉及血小板计数降低、ADP反应受损和依鲁替尼抑制三种机制。

要点

  • CLL出血患者治疗前ADP聚集和血小板计数降低,治疗中ADP聚集持续改善。
  • MCL出血患者治疗前致密颗粒释放降低。
  • 作者认为CLL出血涉及血小板计数降低、ADP反应受损和依鲁替尼抑制。

核心结论

  • 作者认为依鲁替尼相关出血在CLL中涉及三种机制:血小板计数降低(出血与非出血患者间最重要的区分因素)、CLL导致的血小板对ADP反应受损以及依鲁替尼的抑制。
  • 作者认为依鲁替尼初期使平衡偏向出血,但随后因对ADP反应改善而恢复。

研究设计与样本

  • 研究纳入50例CLL和16例MCL患者,使用流式细胞术和光透射聚集法评估依鲁替尼治疗期间的血小板功能活性。
  • 研究比较了治疗前与治疗期间的血小板计数、聚集功能及血小板活化标志物结合。

主要发现

  • 治疗前,CLL和MCL两组患者均有血小板计数降低、ADP诱导聚集受损以及刺激后CD62P、PAC1和膜联蛋白V结合降低。
  • 接受依鲁替尼治疗的CLL患者中28例(56%)发生出血,这些患者治疗前ADP聚集和血小板计数降低;治疗期间血小板计数无变化,ADP聚集持续改善,胶原聚集先降低后升高,与出血呈反相关。
  • MCL患者中10例(62%)发生出血,这些患者治疗前致密颗粒释放降低;依鲁替尼治疗的MCL患者ADP和利托菌素诱导的血小板聚集在治疗期间升高,胶原诱导聚集变化与CLL患者相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Therapy with irreversible Bruton's tyrosine kinase inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is associated with bleeding. OBJECTIVES: To propose the predictive markers of such bleeding, as well as mechanisms responsible for decreased bleeding at later therapy stages. PATIENTS/METHODS: We investigate platelet functional activity in 50 CLL and 16 MCL patients on ibrutinib using flow cytometry and light transmission aggregometry. RESULTS: Prior to treatment, both patient groups had decreased platelet counts; impaired aggregation with adenosine diphosphate (ADP); and decreased binding of CD62P, PAC1, and annexin V upon stimulation. Bleeding in patients treated with ibrutinib was observed in 28 (56%) CLL patients, who had decreased aggregation with ADP and platelet count before therapy. Their platelet count on therapy did not change, platelet aggregation with ADP steadily improved, and aggregation with collagen first decreased and then increased in anticorrellation with bleeding. Bleeding in MCL was observed in 10 (62%) patients, who had decreased dense granule release before therapy. ADP and ristocetin induced platelet aggregation in ibrutinib-treated MCL patients increased on therapy, while collagen-induced aggregation evolved similarly to CLL patients. CONCLUSIONS: Our results suggest that ibrutinib-dependent bleeding in CLL patients involves three mechanisms: decreased platelet count (the most important discriminator between bleeding and non-bleeding patients), impaired platelet response to ADP caused by CLL, and inhibition by ibrutinib. Initially, ibrutinib shifts the balance to bleeding, but then it is restored because of the improved response to ADP.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Dmitrieva EA, Nikitin EA, Ignatova AA, et al. Platelet function and bleeding in chronic lymphocytic leukemia and mantle cell lymphoma patients on ibrutinib. J Thromb Haemost. 2020. PMID: 32511880. doi:10.1111/jth.14943

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。